3 Million+ Unique Research Compounds, Real-time Pricing & Availability
Sign in to enjoy up to 20% OFF or Sign Up
  • Product Search
     
[email protected]
  • Product Search
     
Chemistry
Bioactive Molecules
Screening Libraries
Natural Products
Material Science
ADCs
PEG
Biologics
Consumables
+1 800-931-7508 [email protected]
Sign in to enjoy up to 20% OFF

[CAS NO. 117091-64-2]  Etoposidephosphate

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [117091-64-2]

Distributor
Catalog
AS296868
Brand
Arctom Scientific
CAS
117091-64-2

DESCRIPTION [117091-64-2]

Overview

MDL-
Molecular Weight668.54
Molecular FormulaC29H33O16P
SMILESO=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO4)O3)O[C@@H]4C)O)O)C5=C(C=C6OCOC6=C5)[C@@H](C7=CC(OC)=C(OP(O)(O)=O)C(OC)=C7)[C@]21[H]

For research use only. We do not sell to patients.

56 Publications Citing Use of MCE


Summary

Etoposide phosphate (BMY-40481) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester prodrug of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest, apoptosis , and autophagy [1] [2] .


IC50 & Target

Topoisomerase II


In Vitro

Etoposide phosphate is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4' of the E ring of the etoposide molecule [1] .
Etoposide phosphate (0-1 μM; 72 hours) inhibits HCT116 FBXW +/+ , FBXW -/- and p53 -/- as a dose-dependent manner, exhibits IC 50 values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively [2] .
Etoposide phosphate (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7 -/- cells [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay [2]

Cell Line: FBXW +/+ , FBXW -/- and p53 -/- cell
Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
Incubation Time: 72 hours
Result: Inhibited HCT116 FBXW +/+ , FBXW -/- and p53 -/- cell growth as a concentration manner.

Western Blot Analysis [2]

Cell Line: HCT116 FBXW7 +/+ or FBXW7 -/- cells
Concentration: 25 μM
Incubation Time: 6 hours
Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.

In Vivo

Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8 in female CD-1 mice [3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CD-1 mice [3]
Dosage: 50, 100, or 150 mg/kg
Administration: Intravenous injection; single dose
Result: Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM).

Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT04924101 Merck Sharp & Dohme LLC
Small Cell Lung Cancer
July 15, 2021 Phase 2
NCT00007813 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Amgen|Baxter Healthcare Corporation|Nexell Therapeutics Inc
Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor
May 31, 1997 Phase 1
NCT00589056 Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI)
Lung Cancer
June 2007 Phase 1|Phase 2

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

H 2 O : 125 mg/mL ( 186.97 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.4958 mL 7.4790 mL 14.9580 mL
5 mM 0.2992 mL 1.4958 mL 2.9916 mL
10 mM 0.1496 mL 0.7479 mL 1.4958 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: PBS

    Solubility: 100 mg/mL (149.58 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.


Synonyms

Furo[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-(phosphonooxy)phenyl]-9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-, (5R,5aR,8aR,9S)-
Furo[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-(phosphonooxy)phenyl]-9-[(4,6-O-ethylidene-β-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-, [5R-[5α,5aβ,8aα,9β(R*)]]-
Pyrano[3,2-d]-1,3-dioxin, furo[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one deriv.
(5R,5aR,8aR,9S)-5-[3,5-Dimethoxy-4-(phosphonooxy)phenyl]-9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydrofuro[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
BMY 40481
Etoposide phosphate
Etoposide 4′-phosphate
Etopofos
Etopophos

Information
Shipping
Privacy Notice
Terms of Service
About Us
Contact Us
FAQs
Customer service
Search
Custom Synthesis
My account
My account
Orders
Addresses
Shopping Cart
Suppliers
Supplier Sign In
Become a Supplier
Pay
Follow us
Powered by Arctom Copyright © 2026 Arctom. All rights reserved.